Melanotan-1 (Afamelanotide): MC1R-Selective Agonist and Melanogenesis Research
Development History
Melanotan-1, also known by its pharmaceutical designation afamelanotide, was developed in the 1980s at the University of Arizona by Victor Hruby, Mac Hadley, and colleagues. It emerged from a systematic medicinal chemistry program aimed at creating stable, potent analogs of alpha-melanocyte-stimulating hormone (α-MSH) for use as research tools in melanocortin receptor pharmacology.
The native α-MSH tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) has a circulating half-life of only a few minutes due to rapid enzymatic degradation. The University of Arizona group's approach was to modify the core His-Phe-Arg-Trp pharmacophore to create analogs with enhanced receptor affinity, selectivity, and metabolic stability.
Chemical Structure
Melanotan-1 is a linear tridecapeptide analog of α-MSH with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (MW ~1,647 Da). Two critical modifications distinguish it from native α-MSH:
- Norleucine (Nle) at position 4: Replaces methionine, eliminating the oxidation-prone thioether side chain while maintaining similar hydrophobic character
- D-Phenylalanine (D-Phe) at position 7: The D-configuration of this aromatic residue dramatically increases receptor binding affinity (approximately 100-fold) and confers resistance to endopeptidase cleavage
These substitutions yield a superpotent, metabolically stable melanocortin receptor agonist with a significantly extended biological half-life compared to the native hormone.
Receptor Pharmacology
Melanotan-1 exhibits preferential agonism at the melanocortin 1 receptor (MC1R) relative to other melanocortin receptor subtypes (MC2R–MC5R). MC1R is a Gs-coupled GPCR expressed primarily in melanocytes, where its activation stimulates adenylyl cyclase, increases intracellular cAMP, activates CREB/MITF transcription factors, and ultimately upregulates tyrosinase expression—the rate-limiting enzyme in eumelanin biosynthesis.
Key Published Research
- Sawyer TK et al. (1980) — Original structure-activity relationship studies of α-MSH analogs leading to Melanotan-1 design.
- Dorr RT et al. (2000) — Characterized the melanogenesis-stimulating properties of [Nle⁴, D-Phe⁷]-α-MSH in melanocyte culture models.
- Böhm M et al. (2006) — Reviewed α-MSH analogs and MC1R signaling in photoprotection research.
Future Research Directions
Current research areas include MC1R-mediated DNA repair pathway activation (independent of melanogenesis), investigation of MC1R signaling in non-melanocyte cell types including immune cells and fibroblasts, and development of next-generation MC1R-selective agonists with improved receptor subtype selectivity.
Available at Crush Research: Melanotan-1 10mg. View Certificates of Analysis.
All products are intended for in vitro and laboratory research use only. Not for human or veterinary use.